| CTVA |
Report |
Q2 2026 net sales |
BEAT |
pred ~$6.70B vs. cons $6.59B |
MEDIUM |
| CTVA |
Report |
Q2 2026 operating EPS |
BEAT |
pred ~$2.27 vs. cons $2.23 |
MEDIUM |
| CTVA |
Report |
Q2 2026 operating EBITDA |
BEAT |
pred ~$2.21B vs. cons $2.18B |
LOW |
| CTVA |
Guide |
Operating EPS guidance |
BETTER |
guide ~$3.80 midpoint vs. cons $3.75 (FY2026) |
MEDIUM |
| CTVA |
Guide |
Operating EBITDA guidance |
BETTER |
guide ~$4.25B midpoint vs. cons $4.20B (FY2026) |
MEDIUM |
| CTVA |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.6% |
— |
MEDIUM |
| CTVA |
Return |
5-day cumulative residual |
+0.4% (FADE) |
The projected FY2026 EPS guide of ~$3.80 versus consensus $3.75 largely incorporates the Q2 beat: predicted first-half EPS is ~$3.77 versus consensus ~$3.73, leaving implied second-half EPS of only ~$0.03 versus consensus ~$0.02. With little out-period estimate upside and elevated expectations, the initial positive residual should fade. |
MEDIUM |